Brief: Immunocore Presents Three-Year Overall Survival Data From The Kimmtrak Phase 3 Trial

Immunocore Holdings

21/10/2023 17:32

Oct 21 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE PRESENTS THREE-YEAR OVERALL SURVIVAL DATA FROM
THE
KIMMTRAK PHASE 3 TRIAL
    * IMMUNOCORE - KIMMTRAK DEMONSTRATED LONG-TERM SURVIVAL
BENEFIT IN
HLA-A*02:01 POSITIVE PATIENTS WITH PREVIOUSLY UNTREATED
METASTATIC UVEAL MELANOMA
    * IMMUNOCORE - OVERALL RESPONSE RATE REMAINED IN FAVOR OF
KIMMTRAK
WHEN COMPARED WITH THE CONTROL ARM
    * IMMUNOCORE - NO NEW ADVERSE EVENTS (AES) RELATED TO
LONG-TERM
KIMMTRAK TREATMENT WERE OBSERVED
    * IMMUNOCORE - THE RATE OF DISCONTINUATION DUE TO
TREATMENT-RELATED AES CONTINUED TO BE LOWER (2%) IN THE KIMMTRAK
ARM THAN FOR THE CONTROL ARM (5%)
    * IMMUNOCORE - THERE WERE NO TREATMENT-RELATED DEATHS

Source text for Eikon:  ID:nGNX3zBC3Q 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))